Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

37.09 -0.17 (-0.47%)
Streaming Delayed Price Updated: 1:38 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Preview: Royalty Pharma's Earnings
 
Via Benzinga
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
Ominous Death Cross Forms On Royalty Pharma's Chart
 
Via Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
 
Via Benzinga
Expert Ratings for Royalty Pharma
  Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings: 
Via Benzinga
Royalty Pharma: Q2 Earnings Insights
  Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
From Royalty Pharma plc
Via GlobeNewswire
6 Stocks Warren Buffett Completely Exited in 2022
Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio. 
Via The Motley Fool
Royalty Pharma Announces Expansion of Senior Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
From Royalty Pharma plc
Via GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Royalty Pharma Reports Third Quarter 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
From Royalty Pharma plc
Via GlobeNewswire
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
There may be more trouble on the horizon for these stocks than most investors are seeing right now. 
Via The Motley Fool
Royalty Pharma Declares Fourth Quarter 2022 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added. 
Via Benzinga
Royalty Pharma Announces Expansion of Leadership Team
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces R&D Funding Collaboration With Merck
Novel collaboration structure supports pipeline innovation 
From Royalty Pharma plc
Via GlobeNewswire
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
 
Via Benzinga
Royalty Pharma's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters. 
Via Benzinga
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing. 
Via Benzinga
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it." 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.